Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Cabozantinib, as compared with placebo, doubled median progression-free survival in patients with extrapancreatic neuroendocrine tumors and tripled it in those with pancreatic neuroendocrine tumors.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology